Have you been eager to see how Comerica Incorporated (CMA - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Texas-based money center bank’s earnings release this morning:
An Earnings Beat
Comerica came out with adjusted earnings per share of $1.15, beating the Zacks Consensus Estimate of $1.07. Higher revenues and loan balances along with lower non-interest expenses were primarily responsible for this earnings beat.
How Was the Estimate Revision Trend?
You should note that the earnings estimate for Comerica depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained stable over the last 7 days.
However, Comerica has a decent earnings surprise history. Before posting earnings beat in Q2, the company delivered positive surprises in all the trailing four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 8.7% in the trailing four quarters.
Comerica Incorporated Price and EPS Surprise
Revenue Came In Higher Than Expected
Comerica posted revenues of $776 million, which surpassed the Zacks Consensus Estimate of $770.8 million. Also, it compared favorably with the year-ago number of $713 million.
Key Stats to Note:
- Average total loans: $48.7 billion in Q2, up 1.7% sequentially
- Nonperforming assets: $519 million in Q2, down 18.3% on a year-over-year basis
- Non-interest expenses: $457 million in Q2, down 11.8% on a year-over-year basis
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #2 (Buy) for Comerica. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here)
Check back later for our full write up on this Comerica earnings report!
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>